RG
MRSN

Redmile Group’s Mersana Therapeutics MRSN Stock Holding History

Redmile Group’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-67,945
Closed -$5.59M – 73
2023
Q2 		$5.59M Buy
+67,945
New +$9.94M 0.21% 57

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Redmile Group's MRSN Position: Q3 2023 in Review

Redmile Group sold out of Mersana Therapeutics (MRSN) in Q3 2023, closing a stake of 67,945 shares — an estimated $5.59M sold.

Redmile Group first reported a position in MRSN in Q2 2023 and held it in 1 quarter. The position peaked at $5.59M in Q2 2023. 128 funds tracked by Wall St. Rank hold MRSN as of Q3 2023.

  • Redmile Group reported no remaining Mersana Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Redmile Group sold 67,945 Mersana Therapeutics shares in Q3 2023, an estimated $5.59M.
  • Redmile Group first reported a position in Mersana Therapeutics in Q2 2023 and held it in 1 quarter.
  • Redmile Group's Mersana Therapeutics position peaked at $5.59M in Q2 2023.
  • 128 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2023.

Based on Redmile Group's 13F filing for Q3 2023, filed 14 Nov 2023.